No Data
HUA MEDICINE-B (02552.HK) will hold a Board of Directors meeting on March 27 to consider and approve the annual performance.
Gelonghui reported on March 17 that HUA MEDICINE-B (02552.HK) announced that the Board of Directors meeting is scheduled for March 27, 2025 (Thursday) to consider and approve the annual full-year results of the group for the year ended December 31, 2024, the proposed final dividend (if any), and to address Other matters.
HUA MEDICINE-B: Date of Board Meeting
The bull market for Hong Kong stocks has begun; how to identify the certainty of value growth?
At present, the technical bull market in the Hong Kong stock market is becoming the focus of attention for global investors.
Hong Kong stocks movement | HUA MEDICINE-B (02552) rose nearly 30% in the afternoon. The company has built its own sales team to advance the commercialization process of Huadongning.
HUA MEDICINE-B (02552) rose nearly 30% in the afternoon, as of the time of writing, it rose by 24.12%, trading at 2.11 Hong Kong dollars, with a transaction volume of 20.8871 million Hong Kong dollars.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
HUA MEDICINE-B (02552): HUA MEDICINE Shanghai formally delivered a termination notice to Bayer according to the agreement.
HUA MEDICINE-B (02552) announced that on December 31, 2024, HUA MEDICINE in Shanghai will, according to the agreement, supply to Ba...
Is Hua Medicine (Shanghai) (HKG:2552) Using Debt In A Risky Way?
